Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463–469

Article  CAS  PubMed  Google Scholar 

Vandenberg JI, Walker BD, Campbell TJ (2001) HERG K+ channels: friend and foe. TIPS 22:240–246

CAS  PubMed  Google Scholar 

Hancox JC, McPate MJ, El Harchi A, Zhang YH (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119:118–132

Article  CAS  PubMed  Google Scholar 

Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329–12333

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC (2006) Molecular determinants of HERG channel block. Mol Pharmacol 69:1709–1716

Article  CAS  PubMed  Google Scholar 

Wang W, MacKinnon R (2017) Cryo-EM structure of the open human ether-a-go-go-related K+ channel hERG. Cell 169(3):422–430

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asai T, Adachi N, Moriya T, Oki H, Maru T, Kawasaki M et al (2021) Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole. Structure 29:203–212

Article  CAS  PubMed  Google Scholar 

Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI (2008) Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 74:1443–1452

Article  CAS  PubMed  Google Scholar 

McPate MJ, Duncan RS, Hancox JC, Witchel HJ (2008) Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol 155:957–966

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumagai K, Abe A, Hiraki T, Nakashima A, Oginosawa Y, Ikeda H et al (2000) Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pace - Pacing ClinElectrophysiol 23:1880–1882

Article  CAS  Google Scholar 

Tanabe T, Yoshikawa H, Furuya A, Goto A (1998) Therapeutic effectiveness and plasma levels of single or combination use of class 1 antiarrhythmics for ventricular arrhythmias. Jpn Circ J 52:298–305

Article  Google Scholar 

Millar-Craig MW, Raftery EB (1979) A double-blind trial of disopyramide, procaineamide and digoxin in paroxysmal suptraventricular tachycardia. Clin Cardiol 1979:179–184

Article  Google Scholar 

Taylor EH, Pappas AA (1986) Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. Ann Clin Lab Sci 16:289–295

CAS  PubMed  Google Scholar 

Bauman JL, Gallastegui J, Strasberg B, Swiryn S, Hoff J, Welch WJ et al (1986) Long-term therapy with disopyramide phosphate: side effects and effectiveness. Am Heart J 111:654–660

Article  CAS  PubMed  Google Scholar 

Crijns HJ, Gosselink AT, Lie KT (1996) Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group Cardiovasc Drugs Ther 10:145–152

Article  CAS  Google Scholar 

Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojinowska L et al (2005) Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 45:1251–1258

Article  CAS  PubMed  Google Scholar 

Verlinden NJ, Coons JC (2015) Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. Pharmacotherapy 35(12):1164–1172

Article  CAS  PubMed  Google Scholar 

Proietti R, Russo V, AlTurki A (2019) Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy. Pharmacol Res 143:27–32

Article  CAS  PubMed  Google Scholar 

Lazarra R (1993) Antiarrhythmic drugs and torsade de pointes. Eur Heart J 14:88–92

Article  Google Scholar 

Kurita T, Ohe T, Shimizu W, Suyama K, Aihara N, Takaki H et al (1997) Eearly afterdepolarization-like activity in patients with class 1A induced long QT syndrome and torsades de pointes. Pace - Pacing Clin Electrophysiol 20:695–705

Article  CAS  PubMed  Google Scholar 

Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89:1363–1372

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furushima H, Niwano S, Chinushi M, Ohhira K, Abe A, Aizawa Y (1998) Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans. Heart 79:56–58

Article  CAS  PubMed  PubMed Central  Google Scholar 

Virag L, Varro A, Papp JG (1998) Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn-Schmiedeberg’s Arch Pharmacol 357:268–275

Article  CAS  Google Scholar 

Paul AA, Witchel HJ, Hancox JC (2001) Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Comm 280:1243–1250

Article  CAS  PubMed  Google Scholar 

McPate MJ, Duncan RS, Witchel HJ, Hancox JC (2006) Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 41:563–566

Article  CAS  PubMed  Google Scholar 

El Harchi A, Melgari D, Zhang YH, Zhang H, Hancox JC (2012) Action potential clamp and pharmacology of the variant 1 short QT syndrome T618I hERG K+ channel. PLoS One 7(12):e52451

Article  PubMed  PubMed Central  Google Scholar 

El Harchi A, Zhang YH, Hussein L, Dempsey CE, Hancox JC (2012) Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol 52(1):185–195

Article  PubMed  Google Scholar 

Horikawa M, Yasumuro M, Kanno M, Hanada K, Hashiguchi M, Ogata H (2001) Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolites in rabbits. J Pharm Pharmacol 53(12):1621–1628

Article  CAS  PubMed  Google Scholar 

Lima JJ, Boudoulas H (1987) Stereoselective effects of disopyramide enantiomers in humans. J Cardiovasc Pharmacol 9:594–600

Article  CAS  PubMed  Google Scholar 

Gonzalez T, Arias C, Caballero R, Moreno I, Delpon E, Tamargo J et al (2002) Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block. Br J Pharmacol 137(8):1269–1279

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sintra GL, Carrupt PA, Abriel H, Daina A (2011) Block of the hERG channel by bupivacaine: electrophysiological and modeling insights towards stereochemical optimization. Eur J Med Chem 46(8):3486–3498

Article  Google Scholar 

Grilo LS, Carrupt PA, Abriel H (2010) Stereoselective inhibition of the hERG1 potassium channel. Front Pharmacol 1:137

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra GL, Deglon JJ et al (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabo